IUPAC name
1-({[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)imidazolidine-2,4-dione
SMILES
[O-][N+](=O)C1=CC=C(C=C1)C1=CC=C(O1)C=NN1CC(=O)NC1=O
Compound class
Muscle Relaxants, Central; Musculo-Skeletal System; Muscle Relaxants; Dantrolene and Derivatives; Muscle Relaxants, Directly Acting Agents; CYP3A4 Inhibitors;
Therapeutic area
For use along with appropriate supportive measures for the management of the fulminant hypermetabolism of skeletal muscle characteristic of malignant hyperthermia crises in patients of all ages. Also used preoperatively, and sometimes postoperatively, to prevent or attenuate the development of clinical and laboratory signs of malignant hyperthermia in individuals judged to be malignant hyperthermia susceptible.
Common name
Dantrolene
IUPAC name
1-({[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)imidazolidine-2,4-dione
SMILES
[O-][N+](=O)C1=CC=C(C=C1)C1=CC=C(O1)C=NN1CC(=O)NC1=O
INCHI
InChI=1S/C14H10N4O5/c19-13-8-17(14(20)16-13)15-7-11-5-6-12(23-11)9-1-3-10(4-2-9)18(21)22/h1-7H,8H2,(H,16,19,20)
FORMULA
C14H10N4O5
Common name
Dantrolene
IUPAC name
1-({[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)imidazolidine-2,4-dione
Molecular weight
314.253
clogP
0.949
clogS
-3.299
HBond Acceptor
6
HBond Donor
1
Total Polar Surface Area
126.72
Number of Rings
3
Rotatable Bond
4
